Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)
04 janv. 2022 07h25 HE
|
Arch Biopartners
TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021
05 nov. 2021 17h02 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 5 November 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in...
Novo Nordisk A/S – Share repurchase programme
05 nov. 2021 16h55 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 5 November 2021 — As part of the up to DKK 20.0 billion 2021 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to...
Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity
05 nov. 2021 08h47 HE
|
Novo Nordisk A/S
The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy™ at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placeboThe trial also...
Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
26 juin 2021 16h30 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 26 June 2021 – Novo Nordisk today presented data showing that an investigational 2.0 mg dose of Ozempic® (semaglutide) provided statistically significant and superior reductions in...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
25 mars 2021 08h05 HE
|
Aeterna Zentaris Inc
– Company executing on growth strategy to build-out pipeline of development assets – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021 ...
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
12 janv. 2021 10h05 HE
|
PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...
University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
05 janv. 2021 07h50 HE
|
Arch Biopartners
TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary Cumming School of...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Emisphere Technologies, Inc. Buyout
12 nov. 2020 12h33 HE
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Emisphere Technologies, Inc. (“Emisphere”) (OTC: EMIS) regarding possible breaches...
EMISPHERE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EMIS and Encourages Investors to Contact the Firm
09 nov. 2020 13h46 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...